The value-based medicine comparative effectiveness and cost-effectiveness of penetrating keratoplasty for keratoconus

Cornea

Volumn 27, Issue 9, 2008, Pages 1001-1007

  Roe, Richard H ^a   Lass, Jonathan H ^b   Brown, Gary C ^c,d,e   Brown, Melissa M ^c,d,e  

^a RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Eye Research Institute   (United States)

Author keywords

Comparative effectiveness; Cost utility analysis; Penetrating keratoplasty; Value based medicine

Indexed keywords

ARTICLE; COMPARATIVE STUDY; COMPUTER ANALYSIS; CONTACT LENS; CONTROLLED STUDY; CORNEA TRANSPLANTATION; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; FOLLOW UP; HUMAN; KERATOCONUS; LIFE EXPECTANCY; OUTCOME ASSESSMENT; PENETRATING KERATOPLASTY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; VISUAL ACUITY; ADULT; COST BENEFIT ANALYSIS; ECONOMICS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HOSPITALIZATION; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RETROSPECTIVE STUDY; STANDARD; TREATMENT OUTCOME;

ADULT; COST-BENEFIT ANALYSIS; EVIDENCE-BASED MEDICINE; HEALTH CARE COSTS; HUMANS; KERATOCONUS; KERATOPLASTY, PENETRATING; MULTICENTER STUDIES AS TOPIC; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 58149176020     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31817bb062     Document Type: Article

References (52)

1. Maguire LJ, Meyer RF. Ectatic corneal degenerations. In: Kaufman HE, Barron BA, McDonald MB, Waltman SR, eds. The Cornea. New York, NY: Churchill Livingstone; 1988:485-510.
2. Rabinowitz YS. Keratoconus. Surv Ophthalmol. 1998;42:297-319.
3. Kennedy RH, Bourne WM, Dyer JA. A 48-year clinical and epide-miologic study of keratoconus. Am J Ophthalmol. 1986;101:267-273.
4. Boxer Wachler BS, Christie JP, Chandra NS, et al. Intacs for keratoconus. Ophthalmology. 2003;110:1031-1040.
5. Siganos CS, Kymionis GD, Kartakis N, et al. Management of keratoconus with intacs. Am J Ophthalmol. 2003;135:64-70.
6. Watson SL, Ramsay A, Dart JK, et al. Comparison of deep lamellar keratoplasty and penetrating keratoplasty in patients with keratoconus. Ophthalmology. 2004;111:1676-1682.
7. Paglen PG, Fine MF, Abbott RL, et al. The prognosis for keratoplasty in keratoconus. Ophthalmology. 1982;89:651-654.
8. Kirkness CM, Ficker LA, Steele AD, et al. The success of penetrating keratoplasty for keratoconus. Eye. 1990;4:673-688.
9. Silbiger JS, Cohen EJ, Laibson PR. The rate of visual recovery after penetrating keratoplasty for keratoconus. CLAO J. 1996;22:266-269.
10. Olson RJ, Pingree M, Ridges R, et al. Penetrating keratoplasty for keratoconus: a long-term review of results and complications. J Cataract Refract Surg. 2000;26:987-991.
11. Brierly SC, Izquierdo L Jr, Mannis MJ. Penetrating keratoplasty for keratoconus. Cornea. 2000;19:329-332.
12. Buzard SC, Fundingsland BR. Corneal transplant for keratoconus: results in early and late disease. J Cataract Refract Surg. 1997;23:398-406.
13. Troutman RC, Lawless MA. Penetrating keratoplasty for keratoconus. Cornea. 1987;6:298-305.
14. Lim L, Pesudovs K, Coster DJ. Penetrating keratoplasty for keratoconus: visual outcome and success. Ophthalmology. 2000;107:1125-1131.
15. Lass JH, Lembach RG, Park SB, et al. Clinical management of keratoconus. Ophthalmology. 1990;97:433-445.
16. Arentsen JJ. Corneal transplant allograft reaction: possible predisposing factors. Trans Am Ophthalmol Soc. 1983;81:361-402.
17. Sray WA, Cohen EJ, Rapuano CJ, et al. Factors associated with the need for penetrating keratoplasty in keratoconus. Cornea. 2002;21:784-786.
18. Weinstein MC, Stasson WB. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296:716-721.
19. Torrance GW. Measurement of health state facilities for economic appraisal. A review. J Chronic Dis. 1987;40:593-600.
20. Torrance GW, Feeny D. Utilities and quality-adjusted life years. Int J Technol Assess Health Care. 1989;2:559-575.
21. Gage BF, Cardinalli AB, Albers GW, et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. JAMA. 1995;274:1839-1845.
22. Brown MM, Brown GC, Sharma S, et al. Evidence-based medicine, utilities and quality of life. Curr Opin Ophthalmol. 1999;10:221-226.
23. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Primary Care. Clinics in Office Practice. Philadelphia, PA: W.B. Saunders; 1995.
24. Brown GC. Vision and quality of life. Trans Am Ophthalmol Soc. 1999; 47:473-511.
25. Mendes F, Schaumberg DA, Navon S, et al. Assessment of visual function after corneal transplantation: the quality of life and psychometric assessment after corneal transplantation (Q-PACT) study. Am J Ophthalmol. 2003;135:785-793.
26. Boisjoly H, Gresset J, Fontaine N, et al. The VF-14 index of visual function in recipients of a corneal graft: a 2-year follow-up study. Am J Ophthalmol. 2002;134:166-171.
27. Data™ 3.5 for Healthcare User's Manual. Williamstown, MA: TreeAge Software Inc; 1999: 9-16.
28. Detsky AS, Nagile G, Krahn MD, et al. Primer on medical decision analysis: part 2 - building a tree. Med Decis Making. 1997;17: 126-135.
29. Arias E. United States life tables, 2002. National Vital Statistics Report. 2004;53:1-39.
30. American Medical Association. Cpt 2004: Standard Edition (Cpt/Current Procedural Terminology). Chicago, IL: American Medical Association; 2004.
31. Naimark D, Krahn MD, Naglie G, et al. Primer on medical decision analysis: part 5 - working with Markov processes. Med Decis Making. 1997;17:152-159.
32. Medicare Statistics. Available at: http://www.cms.hhs.gov/manuals/pm- trans/R51Otn.pdf. Accessed February 6, 2004.
33. PDR Staff. 2006 Redbook: Pharmacy's fundamental reference. Thompson PDR, 2006.
34. Seigel JE, Weinstein MC, Russel LB, et al. The panel on cost-effectiveness in health and medicine. JAMA. 1996;276:1339-1341.
35. Redelmeier DA, Detsky AS. A clinician's guide to utility measurement. In: Bergus GR, Cantor SB, eds. Medical Decision Making. Philadelphia, PA: Saunders; 1995:271-280.
36. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. Can Med Assoc J. 1992;146:473-481.
37. Brown MM, Brown GC, Sharma S, et al. Health care economic analyses and value-based medicine. Surv Ophthalmol. 2003;48:204-223.
38. Brown GC, Brown MM, Sharma S. Evidence-Based to Value-Based Medicine. Chicago, IL: AMA Press; 2005:1-324.
39. Brown MM, Brown GC, Sharma S, et al. Quality-of-life associated with unilateral and bilateral good vision. Ophthalmology. 2001;108: 643-647.
40. Agency for Healthcare Research and Quality. Evidence-Based Practice Centers. Available at: http://effectivehealthcare.ahrq.gov/aboutUs/synthesize. cfm. Accessed August 19, 2007.
41. Brown MM, Brown GC, Sharma S, et al. Utility values associated with blindness in an adult population. Br J Ophthalmol. 2001;85:327-331.
42. Busbee B, Brown MM, Brown GC, et al. A cost-utility analysis of cataract surgery in the second eye. Ophthalmology. 2003;110:2310-2317.
43. Membreno JH, Brown MM, Brown GC, et al. A cost-utility analysis of therapy for amblyopia. Ophthalmology. 2002;109:2265-2271.
44. Griffin SC, Barber JA, Manca A, et al. Cost-effectiveness of clinically appropriate decisions on alternative treatments for angina pectoris: prospective observational study. Br Med J. 2007;334:624-627.
45. Jacobson JJ, Schweitzer SO, Kowalski CJ. Chemoprophylaxis of prosthetic joint patients during dental treatment: a decision utility analysis. Oral Surg Oral Med Oral Pathol. 1991;72:167-177.
46. Brown GC, Brown MM, Sharma S, et al. Incremental cost-effectiveness of laser photocoagulation for subfoveal choroidal neovascularization. Ophthalmology. 2000;107:1374-1380
47. Douzdjian V, Escobar F, Kupin WL, et al. Cost-utility analysis of living-donor kidney transplantation followed by pancreas transplantation versus simultaneous pancreas-kidney transplantation. Clin Transpl. 1999;13:51-58.
48. Brown GC, Brown MM, Sharma S, et al. Cost-effectiveness of therapy for threshold retinopathy of prematurity. Pediatrics. 1999;104: 47-64.
49. Cheng AK, Rubin HR, Powe NR, et al. Cost-utility analysis of the cochlear implant in children. JAMA. 2000;284:850-856.
50. Pinkerton SD, Holtgrave DR, Pinkerton HJ. Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV. Arch Intern Med. 1997;167:1972-1980.
51. Smith KJ, Roberts MS. Antiviral therapies for herpes zoster infections. Are they economically justifiable? Pharmacoeconomics. 2000;18:95-104.
52. Brown MM, Brown GC, Sharma S, et al. Quality of life with visual acuity loss from diabetic retinopathy and age-related macular degeneration. Arch Ophthalmol. 2002;120:481-484.